HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

AAV2-mediated gene delivery to monkey putamen: evaluation of an infusion device and delivery parameters.

Abstract
In this study, a modified infusion procedure and a novel infusion device designed for use in humans (Clinical Device B) were evaluated for delivery of recombinant adeno-associated virus (AAV2) to brain. The device is composed of 1.2 m of fused silica inserted through a 24.6-cm surgical steel cannula designed to fit a standard Leksell clinical stereotaxic frame and micro-infusion syringe pump. AAV2 encoding the human aromatic l-amino acid decarboxylase gene (AAV-hAADC-2) was infused into the putamen of 4 normal rhesus monkeys as a supportive study for a clinical trial in Parkinson's disease (PD) patients. Two infusion protocols were tested: a ramped procedure (slow stepwise increases in rate from 0.2 muL/min to 1 muL/min), thought to be essential for convection-enhanced delivery (CED), and a non-ramped infusion at a constant rate of 1 muL/min. The primary endpoints were safety evaluation of the infusion procedures and assessment of transgene expression at 5.5 weeks post-infusion. Clinical observations after vector infusions revealed no behavioral abnormalities during the study period. No differences in gross pathology with either the ramped or non-ramped infusion procedure were observed. Histopathology of the putamen was comparable with both procedures, and revealed only minimal localized inflammatory tissue reaction along the needle track in response to cannula placement and vector infusion. AADC immunohistochemistry demonstrated that vector was distributed throughout the putamen, with no significant difference in volume of immunostaining with either infusion procedure. Serum antibody levels against AAV2 vector exhibited a minor increase after infusion. These results validate the clinical utility of this new infusion device and non-ramped infusion conditions for intraputamenal gene therapy, and have the potential to impact a number of human diseases in which delivery of therapeutics to brain is indicated.
AuthorsLaura M Sanftner, Jurg M Sommer, Brian M Suzuki, Peter H Smith, Sharmila Vijay, Joseph A Vargas, John R Forsayeth, Janet Cunningham, Krys S Bankiewicz, Haihwa Kao, Jan Bernal, Glenn F Pierce, Kirk W Johnson
JournalExperimental neurology (Exp Neurol) Vol. 194 Issue 2 Pg. 476-83 (Aug 2005) ISSN: 0014-4886 [Print] United States
PMID16022872 (Publication Type: Evaluation Study, Journal Article)
Chemical References
  • Aromatic-L-Amino-Acid Decarboxylases
Topics
  • Animals
  • Aromatic-L-Amino-Acid Decarboxylases (genetics)
  • Dependovirus (genetics)
  • Encephalitis (etiology, pathology, physiopathology)
  • Equipment Design
  • Gene Expression Regulation (genetics)
  • Genetic Therapy (adverse effects, instrumentation, methods)
  • Genetic Vectors (genetics, therapeutic use)
  • Infusion Pumps (adverse effects)
  • Macaca mulatta (anatomy & histology, surgery)
  • Parkinson Disease (pathology, physiopathology, therapy)
  • Putamen (pathology, physiopathology, surgery)
  • Recovery of Function (genetics)
  • Syringes (adverse effects, standards)
  • Transfection (methods)
  • Transgenes (genetics)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: